These were Novartis’ Gilenya (fingolimod), Sanofi’s Aubagio (teriflunomide), interferon therapy and Teva’s Copaxone (glatiramer). The analysis showed significant benefits with Tecfidera on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback